ECSP15012804A - Alcoxipirazoles como activadores de guanilato ciclasa soluble - Google Patents

Alcoxipirazoles como activadores de guanilato ciclasa soluble

Info

Publication number
ECSP15012804A
ECSP15012804A ECIEPI201512804A ECPI201512804A ECSP15012804A EC SP15012804 A ECSP15012804 A EC SP15012804A EC IEPI201512804 A ECIEPI201512804 A EC IEPI201512804A EC PI201512804 A ECPI201512804 A EC PI201512804A EC SP15012804 A ECSP15012804 A EC SP15012804A
Authority
EC
Ecuador
Prior art keywords
alcoxypyrazoles
compounds
cyclase activators
soluble
guanilate cyclase
Prior art date
Application number
ECIEPI201512804A
Other languages
English (en)
Inventor
Zhonghua Zhang
Michael D Lowe
John David Ginn
Christopher Ronald Sarko
Edward S Tasber
Jehrod Burnett Brenneman
Original Assignee
Gancia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gancia S P A filed Critical Gancia S P A
Publication of ECSP15012804A publication Critical patent/ECSP15012804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invención se refiere a los compuestos de la Fórmula (I): (I) y a sales de estos aceptables desde el punto de vista farmacéutico, en donde R1 , R2, R3, R4, R5, R6 y R7 son como se definen en la presente. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, procesos para preparar estos compuestos e intermediarios útiles en estos procesos.
ECIEPI201512804A 2012-09-07 2015-04-02 Alcoxipirazoles como activadores de guanilato ciclasa soluble ECSP15012804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261697899P 2012-09-07 2012-09-07

Publications (1)

Publication Number Publication Date
ECSP15012804A true ECSP15012804A (es) 2015-12-31

Family

ID=49170904

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201512804A ECSP15012804A (es) 2012-09-07 2015-04-02 Alcoxipirazoles como activadores de guanilato ciclasa soluble

Country Status (38)

Country Link
US (2) US8906904B2 (es)
EP (1) EP2892891B1 (es)
JP (1) JP5970134B2 (es)
KR (1) KR101692707B1 (es)
CN (1) CN104619695B (es)
AP (1) AP2015008231A0 (es)
AR (1) AR092869A1 (es)
AU (1) AU2013312931B2 (es)
BR (1) BR112015004529B1 (es)
CA (1) CA2880494C (es)
CL (2) CL2015000255A1 (es)
CY (1) CY1122610T1 (es)
DK (1) DK2892891T3 (es)
EA (1) EA027244B1 (es)
EC (1) ECSP15012804A (es)
ES (1) ES2748798T3 (es)
GE (1) GEP20176631B (es)
HK (1) HK1210164A1 (es)
HR (1) HRP20191755T1 (es)
HU (1) HUE046996T2 (es)
IL (1) IL236987A (es)
LT (1) LT2892891T (es)
MA (1) MA37891B1 (es)
MD (1) MD4425C1 (es)
MX (1) MX338887B (es)
NZ (1) NZ703989A (es)
PE (1) PE20151001A1 (es)
PH (1) PH12015500457B1 (es)
PL (1) PL2892891T3 (es)
PT (1) PT2892891T (es)
RS (1) RS59394B1 (es)
SG (2) SG11201500861QA (es)
SI (1) SI2892891T1 (es)
TN (1) TN2015000054A1 (es)
TW (1) TWI586661B (es)
UA (1) UA115881C2 (es)
UY (1) UY35012A (es)
WO (1) WO2014039434A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039434A1 (en) * 2012-09-07 2014-03-13 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
SG11201700507XA (en) 2014-07-22 2017-02-27 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
RU2018126349A (ru) 2015-12-18 2020-01-20 Новартис Аг Индановые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
KR20210008070A (ko) 2018-05-15 2021-01-20 바이엘 악티엔게젤샤프트 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
MA53118A (fr) * 2018-07-12 2021-05-19 Boehringer Ingelheim Int Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
CN112079712B (zh) * 2020-09-18 2022-12-13 江苏美迪克化学品有限公司 一种对乙烯基水杨酸的制备方法
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023183213A1 (en) 2022-03-21 2023-09-28 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating portal hypertension
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
EP1344289A4 (en) 2000-11-22 2005-08-31 Visx Inc THERMOSTATIC POSITIONING DEVICE FOR NONLINEAR OPTICAL ELEMENTS
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
CN101222923A (zh) 2005-07-18 2008-07-16 拜耳医药保健股份公司 可溶性鸟苷酸环化酶活化剂和刺激剂用于预防或治疗肾脏疾病的新用途
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders
EP2197551B1 (en) * 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MX2010003071A (es) * 2007-10-05 2010-04-01 Sanofi Aventis Deutschland Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
AR069517A1 (es) * 2007-12-03 2010-01-27 Smithkline Beecham Corp Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2010081647A2 (en) * 2009-01-17 2010-07-22 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
RU2011138970A (ru) 2009-02-26 2013-04-10 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
RS54336B1 (en) * 2010-02-05 2016-02-29 Adverio Pharma Gmbh SGC STIMULATORS OR SGC ACTIVATORS, ONLY FOR YOURSELF AND COMBINED WITH PDE5 INHIBITORS FOR CYST FIBROSIS TREATMENT
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
DK2576548T3 (en) * 2010-05-26 2015-09-28 Adverio Pharma Gmbh USE OF sGC stimulators, sGC activators alone and in combination with PDE5 inhibitors for treating systemic sclerosis (SSc)
EP2687210A1 (de) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
US8815857B2 (en) 2011-08-12 2014-08-26 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
WO2014039434A1 (en) * 2012-09-07 2014-03-13 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators

Also Published As

Publication number Publication date
HRP20191755T1 (hr) 2019-12-27
CY1122610T1 (el) 2021-03-12
UA115881C2 (uk) 2018-01-10
SG10201510668UA (en) 2016-01-28
PT2892891T (pt) 2019-11-05
WO2014039434A1 (en) 2014-03-13
MD4425C1 (ro) 2017-01-31
EA201500298A1 (ru) 2015-08-31
AP2015008231A0 (en) 2015-01-31
TWI586661B (zh) 2017-06-11
US8906904B2 (en) 2014-12-09
HK1210164A1 (en) 2016-04-15
NZ703989A (en) 2017-04-28
SG11201500861QA (en) 2015-04-29
MA37891B1 (fr) 2018-05-31
CN104619695B (zh) 2018-04-10
PL2892891T3 (pl) 2020-01-31
CA2880494C (en) 2021-09-21
USRE46886E1 (en) 2018-06-05
PE20151001A1 (es) 2015-07-15
CN104619695A (zh) 2015-05-13
US20140073629A1 (en) 2014-03-13
BR112015004529A2 (pt) 2017-07-04
BR112015004529B1 (pt) 2022-06-21
PH12015500457A1 (en) 2015-04-20
AR092869A1 (es) 2015-05-06
BR112015004529A8 (pt) 2019-08-27
KR101692707B1 (ko) 2017-01-04
DK2892891T3 (da) 2019-10-14
CL2015000255A1 (es) 2015-05-29
TW201422607A (zh) 2014-06-16
LT2892891T (lt) 2020-01-27
ES2748798T3 (es) 2020-03-18
CL2015000562A1 (es) 2015-06-12
MX2015002807A (es) 2015-05-15
CA2880494A1 (en) 2014-03-13
UY35012A (es) 2014-03-31
IL236987A (en) 2017-02-28
MD4425B1 (ro) 2016-06-30
MA37891A1 (fr) 2018-01-31
EP2892891A1 (en) 2015-07-15
AU2013312931B2 (en) 2017-06-22
SI2892891T1 (sl) 2019-11-29
JP5970134B2 (ja) 2016-08-17
GEP20176631B (en) 2017-02-27
RS59394B1 (sr) 2019-11-29
EA027244B1 (ru) 2017-07-31
EP2892891B1 (en) 2019-07-31
JP2015527394A (ja) 2015-09-17
TN2015000054A1 (en) 2016-06-29
PH12015500457B1 (en) 2015-04-20
KR20150048765A (ko) 2015-05-07
MD20150019A2 (ro) 2015-07-31
AU2013312931A1 (en) 2015-02-05
HUE046996T2 (hu) 2020-04-28
MX338887B (es) 2016-05-04

Similar Documents

Publication Publication Date Title
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY32574A (es) Antagonistas del receptor cxcr3
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
ECSP15029822A (es) Derivados de imidazopiridazina como moduladores del receptor gabaa
DOP2017000034A (es) Compuestos de imidazopiridazina
CR20150171A (es) Benzamidas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
DOP2012000061A (es) Utilizacion de derivados del indol como activadores de nurr-1, para la aplicacion en tratamientos de enfermedades como el parkinson
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa